On June 7, 2022 Ichnos Sciences Inc., a clinical-stage global biotechnology company developing innovative multispecific antibodies for oncology, reported that its president and chief executive officer, Cyril Konto, M.D., will present at the 2022 Jefferies Healthcare Conference in New York on Wednesday, June 8 at 3:30 PM Eastern Time (Press release, Ichnos Sciences, JUN 7, 2022, View Source [SID1234615732]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Ichnos has been working to develop and advance therapies for cancer that extend and improve survival and quality of life, driven by the belief that cure is possible," said Cyril Konto, M.D., President and Chief Executive Officer of Ichnos Sciences. "We are excited to come together with other health and biotech innovators at the Jefferies Conference and honored to have the opportunity to share our plans for shifting medicine forward."

Dr. Konto’s presentation comes just weeks after Ichnos announced the selection of its ISB 2001 TREAT1 trispecific antibody, the first T cell-engaging antibody that targets BCMA and CD38 on multiple myeloma cells, as its next candidate to move into clinical development. Ichnos’ pipeline also includes ISB 1342, a CD38 x CD3 bispecific antibody, which continues to enroll patients with relapsed/refractory multiple myeloma in an ongoing Phase 1, dose escalation and expansion study, and ISB 1442, a CD38 x CD47 biparatopic bispecific antibody for which a Phase 1 study in relapsed/refractory multiple myeloma is planned to start shortly.

A live webcast of the presentation can be accessed through this link. A replay of the webcast will be available for one year following the conference.